Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Products for Apoptosis
- Caspase(99)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(43)
- Bax(7)
- Bcl-2 Family(120)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(66)
- MDM2(12)
- p53(123)
- PC-PLC(4)
- PKD(7)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(145)
- Other Apoptosis(883)
- APC(6)
- PD-1/PD-L1 interaction(90)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(31)
- Cat.No. 产品名称 Information
-
GC15828
AMG232
2-((3R,5R,6S)-5-(3-氯苯基)-6-(4-氯苯基)-1-((S)-1-(异丙基磺酰基)-3-甲基丁烷-2-基)-3-甲基-2-氧代哌啶-3-基)乙酸,AMG 232;AMG-232
An inhibitor of the MDM2 and p53 interaction -
GC13589
CID 755673
An inhibitor of protein kinase D
-
GC12332
NU 7026
2-(4-吗啉基)-4H-萘并[1,2-B]吡喃-4-酮,LY293646
Inhibitor of DNA-dependent protein kinase -
GC15866
Capecitabine
卡培他滨
A prodrug of 5-fluorouracil -
GC13317
WEHI-539 hydrochloride
A selective Bcl-xL inhibitor
-
GC12391
Xanthohumol
黄腐醇
A natural prenylated chalcone
-
GC10824
DBeQ
JRF 12
A selective inhibitor of the ATPase p97 -
GC10350
TIC10 isomer
ONC201 isomer
TIC10异构体是TIC10的异构体。 -
GC12773
Palomid 529
P529
An inhibitor of mTORC1 and mTORC2 formation -
GC12337
Tenovin-3
Tenovin 3;Tenovin3
A small molecule activator of p53 -
GC11224
BI6727(Volasertib)
伏拉塞替; BI 6727
A polo-like kinase inhibitor -
GC16821
TAE226(NVP-TAE226)
TAE 226;TAE-226
A dual inhibitor of FAK and IGF-1R -
GC15022
Vandetanib (ZD6474)
凡德他尼; ZD6474
A multi-kinase inhibitor -
GC17648
Dinaciclib(SCH727965)
(2S)-1-[3-乙基-7-[[(1-氧代-3-吡啶基)甲基]氨基]吡唑并[1,5-A]嘧啶-5-基]-2-哌啶乙醇,SCH 727965
A CDK inhibitor -
GC13070
Cytarabine
阿糖胞苷; Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C
Cytarabine(Ara-C)是一种胞嘧啶类似物,主要抑制DNA聚合酶的功能来阻断DNA合成。 -
GC15739
CHIR-124
4-[((3S)-1-氮杂双环[2,2,2]辛-3-基)氨基]-3-(1H-苯并咪唑-2-基)-6-氯喹啉-2(1H)-酮
A selective Chk1 inhibitor -
GC13671
Busulfan
白消安
An alkylating antineoplastic agent -
GC13286
ZM336372
An activator of the Raf-1 signalling pathway
-
GC13803
Triflurdine (Viroptic)
曲氟尿苷; Trifluorothymidine; 5-Trifluorothymidine; TFT
A thymidine analog that inhibits DNA synthesis -
GC10978
Terfenadine
特非那定; (±)-Terfenadine; MDL-991
A selective histamine H1-receptor antagonist -
GC10585
Simvastatin (Zocor)
辛伐他汀; MK 733
An HMG-CoA reductase inhibitor -
GC12116
Pitavastatin Calcium
匹伐他汀钙; NK-104 hemicalcium; Pitavastatin hemicalcium
An HMG-CoA reductase inhibitor -
GC17318
Orlistat
奥利司他; Tetrahydrolipstatin; Ro-18-0647
奥利司他是胰脏和胃中脂肪酶的不可逆抑制剂,是治疗肥胖症的药物。 -
GC16145
NVP-BGT226
NVP-BGT226 maleate
A dual PI3K and mTOR inhibitor -
GC14075
Nocodazole
诺考达唑
Nocodazole是一种抗有丝分裂药物,是一种快速可逆的微管聚合抑制剂,在无细胞试验中抑制Abl,Abl(E255K)和Abl(T315I),IC50值分别为0.21μM,0.53μM和0.64μM。 -
GC16976
Mitotane (Lsodren)
米托坦; 2,4′-DDD; o,p'-DDD
An inhibitor of steroidogenesis -
GC11762
Meloxicam (Mobic)
美洛昔康
A selective COX-2 inhibitor -
GC17057
Lithocholic Acid
石胆酸; 3α-Hydroxy-5β-cholanic acid
A toxic secondary bile acid -
GC10474
Laquinimod (ABR-215062)
拉喹莫德; ABR-215062
An immunomodulator -
GC17866
INCB28060
卡马替尼; INC280; INCB28060
An inhibitor of HGFR (c-Met) -
GC16880
Flurbiprofen
氟比洛芬; dl-Flurbiprofen
A non-selective COX inhibitor -
GC15605
Ezetimibe
依泽替米贝; SCH 58235
A cholesterol transport inhibitor -
GC13029
AZD2014
3-[2,4-双((3S)-3-甲基吗啉-4-基)吡啶并[5,6-E]嘧啶-7-基]-N-甲基苯甲酰胺,AZD 2014; AZD-2014
A potent dual mTORC1/2 inhibitor -
GC15055
AZ 628
AZ-628; AZ628
A Raf kinase inhibitor -
GC11786
Acetylcysteine
乙酰半胱氨酸; N-Acetylcysteine; N-Acetyl-L-cysteine; NAC
乙酰半胱氨酸是半胱氨酸的 N-乙酰基衍生物。 -
GC15281
K-252c
孢菌素甙元,Staurosporinone
A cell-permeable PKC inhibitor -
GC14256
Tivantinib (ARQ 197)
(3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮,ARQ-197;ARQ197
An inhibitor of c-Met -
GC10970
WP1130
WP 1130; WP-1130
A deubiquitinase inhibitor -
GC11908
Cisplatin
顺铂; cis-Platinum; CDDP; cis-Diaminodichloroplatinum
顺铂是最好的、最早的基于金属的化疗药物之一,用于治疗广泛的实体癌症,如睾丸癌、卵巢癌、膀胱癌、肺癌、宫颈癌、头颈部肿瘤和胃癌等。 -
GC10225
Dacomitinib (PF299804, PF299)
达克替尼; PF-00299804; PF-299804
A pan-ErbB receptor tyrosine kinase inhibitor -
GC15904
PP242
PP242; PP-242
Potent inhibitor of mTOR kinase in both mTORC1 and mTORC2 -
GC15134
Fludarabine Phosphate (Fludara)
磷酸氟达拉滨; NSC 118218 phosphate
A prodrug form of fludarabine and 2-fluoro-ara-ATP -
GC12573
Temsirolimus
西罗莫司脂化物,Torisel;CCI-779;CCI 779;CCI779
A specific inhibitor of mTOR activity -
GC15818
RAF265
CHIR-265;RAF 265;RAF-265;CHIR265
A B-Raf and VEGFR2 inhibitor -
GC15680
Perifosine
哌立福新; KRX-0401; NSC 639966; D21266
Perifosine 是 Akt 的抑制剂 。
-
GC10647
FR 180204
ERK Inhibitor II
A potent, cell-permeable inhibitor of ERK1/2 -
GC16436
Tenovin-6
A small molecule activator of p53
-
GC12508
Nutlin-3b
4-[[(4R,5S)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮
The less active enantiomer of (–)-nutlin-3 -
GC17785
Macitentan
马西替坦; ACT-064992
A dual ETA/ETB receptor antagonist -
GC10944
Butein
紫铆因; 2’,3,4,4’-tetrahydroxy Chalcone
A plant polyphenol